Aquestive Therapeutics Inc (AQST) Institutional Holdings & 13F Data (Q2 2026)

AQST ranks #3156 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AQST is a top-conviction position for Bratton Capital Management, L.P. — at 100.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Sugar Maple Asset Management, LLC has added to its AQST position for two straight quarters, increasing it by $301.0K to reach $542.0K today.

AQST is down 6.9% today, but institutions show net buying of $29.5M this quarter — a divergence between today's price move and the underlying institutional flow.

AQST reported a net loss of $78.2M over the trailing twelve months.

• Not yet profitable — net loss of $78.2M over the trailing twelve months
• Revenue grew 22.6% year over year
• Net income declined year over year, from -$65.0M to -$78.2M
• Operating cash flow was negative, using $52.4M in cash
• Current ratio of 3.14x — enough short-term assets to cover short-term liabilities